Tag: investor

Landmark FDA Approval Is an Important Milestone in Retina Care, Bringing Patients and Physicians an Ophthalmic Bevacizumab Developed Specifically for the Eye Following Years of Rigorous Clinical and Regulatory Evaluation

Phoenix, July 23, 2026 (GLOBE NEWSWIRE) -- Cavco Industries, Inc. (Nasdaq: CVCO) will release earnings for the first quarter ended June 27, 2026 on Thursday, July 30, 2026 after the close of market. Senior management will discuss the results in a live webcast the following day, Friday, July 31, 2026 at 1:00 p.m. Eastern Time.

BEVERLY, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- ATN International, Inc. (“ATN” or the “Company”) (Nasdaq: ATNI), a provider of digital infrastructure and communications services, announced today that it will release its second quarter 2026 financial results on Wednesday, August 5, 2026, after market close. The Company will host a conference call to discuss the results starting at 11:00 a.m. Eastern time on Thursday, August 6, 2026.

Bengaluru, India, July 23, 2026 (GLOBE NEWSWIRE) -- Zoomcar Holdings, Inc. (OTCQB: ZCAR) (the “Company”), the leading peer-to-peer self-drive car-sharing marketplace in India, today announced that it is extending the expiration date of its previously announced offer to exchange (the “Offer to Exchange”) certain outstanding warrants for shares of the Company’s common stock.

HOUSTON, July 23, 2026 (GLOBE NEWSWIRE) -- Archrock, Inc. (NYSE: AROC) (“Archrock” or the “Company”) today announced that its Board of Directors has declared an increased quarterly dividend of $0.23 per share of common stock, or $0.92 per share on an annualized basis. The second quarter 2026 dividend will be paid on August 11, 2026, to all stockholders of record on August 4, 2026.

ST. JOHN'S, Newfoundland and Labrador, July 23, 2026 (GLOBE NEWSWIRE) --

Fortis Inc. ("Fortis" or the "Corporation") (TSX/NYSE: FTS) will release its second quarter 2026 financial results on Friday, July 31, 2026. A teleconference and webcast will be held the same day at 8:30 a.m. (Eastern). David Hutchens, President and Chief Executive Officer and Jocelyn Perry, Executive Vice President and Chief Financial Officer will discuss the Corporation's second quarter financial results.

Second Quarter 2026

ROCKVILLE, Md., July 22, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it will report second quarter 2026 financial and business results after the market closes on Tuesday, August 4, 2026.